RESUMEN

Asthma, allergic rhinitis, chronic urticaria, and atopic dermatitis are common diseases that affect hundreds of thousands of pregnant women each year. The authors discuss the use of biologics in women who are pregnant or lactating, indications, available safety information, and knowledge gaps. There are pregnant patients for which standard treatment is either inadequate or contraindicated; in those cases, monoclonal antibodies (biologics) should be considered despite the unknown risk to the fetus. In severe asthma, omalizumab is the best studied with reassuring available safety data. Insufficient safety data exist on mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab use during pregnancy and lactation.

Asunto(s)

Asma , Productos Biológicos , Dermatitis Atópica , Rinitis Alérgica , Embarazo , Femenino , Humanos , Dermatitis Atópica/tratamiento farmacológico , Lactancia , Anticuerpos Monoclonales/uso terapéutico , Productos Biológicos/uso terapéutico , Asma/tratamiento farmacológico